nivolumabpembrolizumab
…city, with G3/4 events reported in 22% compared with 14% in the nivolumab monotherapy arm. An update presented at the European Society of…
6articles mentioning drugs
21drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: dostarlimab ×
dostarlimab
This drug is selected. Its supporting articles are shown below.
Articles mentioning dostarlimab
6 articles · page 1 of 1pembrolizumabDurvalumabdostarlimabatezolizumab
… therapeutic positioning.Aim and Objectives To evaluate whether pembrolizumab, dostarlimab, durvalumab, durvalumab plus olaparib, and atezoli…
durvalumabPembrolizumabdostarlimabatezolizumabOlaparibpMMRendometrial cancer
…erapy –specifically those including pembrolizumab, dostarlimab, durvalumab, durvalumab plus olaparib, and atezolizumab–, in the treatment …
dostarlimabrectal cancerantiviral therapy
…in his early 40s was receiving treatment for rectal cancer with dostarlimab, an immune checkpoint inhibitor (ICI), when he developed fevers…
pembrolizumabdurvalumabdostarlimabtremelimumabnivolumabatezolizumabcemiplimabavelumabipilimumabimmunotherapy+2 more
…Results In 2023 and 2024 we used seven immunotherapeutic drugs: pembrolizumab (230 patients), durvalumab (45 patients), atezolizumab (45 pati…
nivolumabpembrolizumabipilimumabatezolizumabavelumabcemiplimabdurvalumabdostarlimabrelatlimabBurkitt’s Lymphoma+1 more
…114 male and 50 female (unspecified 17). The ICIs involved were nivolumab (n=68), pembrolizumab (n=51), ipilimumab (n=35), atezolizumab (…